Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Equity Average (2016 - 2025)

Regenxbio has reported Equity Average over the past 11 years, most recently at $132.1 million for Q4 2025.

  • Quarterly results put Equity Average at $132.1 million for Q4 2025, down 52.91% from a year ago — trailing twelve months through Dec 2025 was $132.1 million (down 52.91% YoY), and the annual figure for FY2025 was $181.2 million, down 36.58%.
  • Equity Average for Q4 2025 was $132.1 million at Regenxbio, down from $187.6 million in the prior quarter.
  • Over the last five years, Equity Average for RGNX hit a ceiling of $727.0 million in Q1 2022 and a floor of $132.1 million in Q4 2025.
  • Median Equity Average over the past 5 years was $410.0 million (2023), compared with a mean of $421.2 million.
  • Biggest five-year swings in Equity Average: surged 55.96% in 2022 and later plummeted 52.91% in 2025.
  • Regenxbio's Equity Average stood at $612.9 million in 2021, then dropped by 11.89% to $540.0 million in 2022, then tumbled by 37.52% to $337.4 million in 2023, then decreased by 16.86% to $280.5 million in 2024, then plummeted by 52.91% to $132.1 million in 2025.
  • The last three reported values for Equity Average were $132.1 million (Q4 2025), $187.6 million (Q3 2025), and $243.9 million (Q2 2025) per Business Quant data.